PD-L1 is Fascinating but IDO Needs Attention in Non-HCV and Non-HBV-Associated Hepatocellular Carcinoma Patients.
Kashif AsgharShaarif BashirIftikhar Ali RanaMuhammad Abu BakarAsim FarooqMuhammad HassanZukhruf AsifMahnoor AfzalIqra MasoodMuhammad IshaqMuhammad TahseenSundus BilalShafqat MehmoodNosheen KanwalIslah Ud DinAsif LoyaPublished in: Journal of hepatocellular carcinoma (2023)
Evaluation of IDO and PD-L1 expression may add therapeutic advantage in non-HCV and non-HBV-associated HCC patients that overexpress IDO. Further validation in a larger cohort is warranted.